All Stories

  1. Bladder Cancer Burden in the USA: Population Scenarios for 2040
  2. The cost of non-drug interventions that improve function and reduce dementia-related behaviors
  3. Public-health impact of increasing human papillomavirus vaccination and cervical cancer screening
  4. Reply to: Comment on Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness
  5. Data from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  6. Supplementary Figure S1 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  7. Supplementary Figure S2 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  8. Supplementary Table S1 from Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study
  9. Long-term trends in bladder cancer incidence using a harmonized staging variable – A SEER-based study
  10. Benefits of colorectal cancer screening using FIT with varying positivity thresholds by age and sex
  11. Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer
  12. A Tutorial on Discrete Event Simulation Models in R Using a Cost-Effectiveness Analysis Example
  13. Discrete-Event Simulation Model for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source Pipeline
  14. Calculating epidemiological outcomes from simulated longitudinal data
  15. Cost-Effectiveness of Using Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence Among Male Sex Workers
  16. A microsimulation-based framework for mitigating societal bias in primary care data
  17. Cost-effectiveness of enfortumab vedotin and pembrolizumab for first-line metastatic urothelial cancer in the United States
  18. Utility Values of Health Status in Gastric Cancer: A Systematic Review
  19. A novel decision modeling framework for health policy analyses when outcomes are influenced by social and disease processes
  20. A Fast Nonparametric Sampling Method for Time to Event in Individual-Level Simulation Models
  21. Microsimulation Estimates of Decision Uncertainty and Value of Information Are Biased but Consistent
  22. State-level disparities in cervical cancer prevention and outcomes in the U.S.: a modeling study
  23. Primary HPV screening compared with other cervical cancer screening strategies in women with HIV: a cost-effectiveness study
  24. Helicobacter pylori infection in the United States beyond NHANES: a scoping review of seroprevalence estimates by racial and ethnic groups
  25. Birth cohort and age-specific trends in global Helicobacter pylori seroprevalence: a scoping review
  26. Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico
  27. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision
  28. State-level disparities in cervical cancer prevention and impact on outcomes in the U.S.: A modeling study
  29. Emulator-Based Bayesian Calibration of the CISNET Colorectal Cancer Models
  30. Characteristics of a cost-effective blood test for colorectal cancer screening
  31. A Fast Nonparametric Sampling (NPS) Method for Time-to-Event in Individual-Level Simulation Models.
  32. Using Age-Specific Rates for Parametric Survival Function Estimation in Simulation Models
  33. Value of Information: Success Stories
  34. Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics
  35. Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program
  36. NordICC Trial Results in Line With Expected Colorectal Cancer Mortality Reduction After Colonoscopy: A Modeling Study
  37. Breastfeeding is associated with the intelligence of school‐age children in Mexico
  38. Cost effectiveness of non‐drug interventions that reduce nursing home admissions for people living with dementia
  39. Emulator-based Bayesian calibration of the CISNET colorectal cancer models
  40. Effects of Mitigation and Control Policies in Realistic Epidemic Models Accounting for Household Transmission Dynamics
  41. A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
  42. Dynamics of Respiratory Infectious Diseases in Incarcerated and Free-Living Populations: A Simulation Modeling Study
  43. An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example
  44. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
  45. Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models
  46. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis
  47. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study
  48. Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-Naïve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico
  49. Age-specific rates of onset of cannabis use in Mexico
  50. Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies
  51. Effectiveness of COVID-19 Vaccines among Incarcerated People in California State Prisons: A Retrospective Cohort Study
  52. COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors
  53. Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study
  54. Prioritizing Research Informing Antibiotic Prophylaxis Guidelines for Knee Arthroplasty Patients
  55. BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling
  56. Covid-19 Vaccine Acceptance in California State Prisons
  57. Outbreaks of Covid-19 Variants in Prisons: A Mathematical Modeling Analysis of Vaccination and Re-Opening Policies
  58. Covid-19 in the California State Prison System: An Observational Study of Decarceration, Ongoing Risks, and Risk Factors
  59. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries
  60. How do Covid-19 policy options depend on end-of-year holiday contacts in Mexico City Metropolitan Area? A Modeling Study
  61. Age-Specific Rates of Onset of Cannabis Use in Mexico
  62. The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review
  63. A Summary of the 2020 Gastric Cancer Summit at Stanford University
  64. Estimating population-based recurrence rates of colorectal cancer over time in the United States
  65. Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation
  66. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
  67. Validation of Microsimulation Models Used for Population Health Policy
  68. Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers
  69. Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods
  70. Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies
  71. A Multidimensional Array Representation of State-Transition Model Dynamics
  72. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis
  73. Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio
  74. Midwife‐led care and obstetrician‐led care for low‐risk pregnancies: A cost comparison
  75. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
  76. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
  77. A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
  78. A Multidimensional Array Representation of State-Transition Model Dynamics
  79. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies
  80. “Time Traveling Is Just Too Dangerous” but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier
  81. The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis
  82. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer
  83. Nonidentifiability in model calibration and its implications for medical decision making.
  84. Revisiting assumptions about age-based sexual mixing representations in mathematical models
  85. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis
  86. Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model – CORRIGENDUM
  87. Force of infection of Helicobacter pylori in Mexico: evidence from a national survey using a hierarchical Bayesian model
  88. Microsimulation modeling in R: A tutorial
  89. A Kinked Health Insurance Market: Employer-Sponsored Insurance under the Cadillac Tax
  90. A Gaussian Approximation to efficiently compute the expected value of sample information (EVSI)
  91. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
  92. Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?
  93. An Overview of R in Health Decision Sciences
  94. Modeling the Cost-Effectiveness of Doula Care Associated with Reductions in Preterm Birth and Cesarean Delivery
  95. Análisis de costo-beneficio: prevención del VIH/sida en migrantes en Centroamérica
  96. Registro de señales de EEG para aplicaciones de Interfaz Cerebro Computadora (ICC) basado en Potenciales Evocados Visuales de Estado Estacionario (PEVEE)